Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICN Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Carl Wysocki who wrote (808)	4/1/1998 5:46:00 PM
From: Johnnie W.	Read Replies (1) \| Respond to of 1029

Good points, all I wanted to bring up is that no one had mentioned today's announcement of the Lillt partnership......This partnership is key!!!

To: Carl Wysocki who wrote (808)	4/1/1998 9:11:00 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 1029

I agree with that IJF fellow on Yahoo, since he's me. The PE which you disagree with (its hard for me to accept easily) is from the statement in the Goldman Sachs report that ICN's faster growth rate justifies a PE 20% higher than the other drug companies. But what do I know, I'm no drug analyst. On the idea of a buyout. It seems to me that ICN becoming a major drug distribution firm in Eastern Europe and Russia, mitigates against a purchase by a major drug company. Would Merck want Lilly distributing it's products? ICN is really a non-threatening player to operate a distribution company and thus all the majors can deal with it and not be threatened. A lot of the value would be lost if a major player bought ICN. Therefore, I don't think it will happen if the distribution business grows to be the principal value of ICN. Two issues could put ICN in play. Loss of Panic (I think he would be difficult or impossible to replace) or a battle between Roche and SGP for control of Rebetol to use with their interferon A products in Europe (the last major uncommitted market for rebetol). Hope ICN stays independent. Think it is in our best interest. Time will tell.